NICE has assessed 3 devices, NIOX MINO, NIOX VERO and NObreath, to help the NHS decide whether to use these products.
The devices are used for measuring the amount of forced exhaled nitric oxide in the breath (called FeNO). Nitric oxide is produced in the lungs and some of it is breathed out. Increased levels of nitric oxide in the breath are thought to be related to lung inflammation and asthma. Also, FeNO levels in the breath can be lowered by effective asthma treatment with inhaled corticosteroids (preventers). So, measuring FeNO in the breath may help in the diagnosis and management of asthma.
NICE has recommended FeNO testing to help diagnose asthma in adults and children when diagnosis is unclear. It has also recommended FeNO testing to help manage asthma in people who have symptoms despite using inhaled corticosteroids.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.